Omnimmune Holdings, Inc. (OMMH) news stock charts
Omnimmune Holdings, Inc. (OMMH/OMMH.OB) Investment Summary:
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies and a multivalent phase I cancer vaccine targeting two epitopes of HER-2, validated tumor associated antigens. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines, monoclonal antibodies, and gene-based products, which target a hormone called human chorionic gonadotropin. The company is based in Houston, Texas.1 Employees
OMNIMMUNE HOLDINGS INC (OMMH:OTC Bulletin Board Market)
LAST $0.03 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of 8:10 PM 03/16/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of OMNIMMUNE HOLDINGS INC (OMMH)
|
OPEN
$0.03
|
PREVIOUS CLOSE
$0.03
|
|
|
DAY HIGH
$0.03
|
DAY LOW
$0.03
|
|
|
52 WEEK HIGH
03/26/09 - $0.85
|
52 WEEK LOW
03/16/10 - $0.03
|
|
|
MARKET CAP
222.9K
|
AVERAGE VOLUME 10 D
7.1K
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
8.9M
|
|
|
OMMH Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for OMNIMMUNE HOLDINGS INC (OMMH)
Omnimmune Holdings, Inc. announced delayed 10-Q filing
11/16/2009
On 11/16/2009, Omnimmune Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Omnimmune Holdings Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2009
08/20/2009
Omnimmune Holdings Inc. reported earnings results for the second quarter ended June 30, 2009. For the quarter, the company's net loss for the quarter was $458,984, up from $3.02 million for the same quarter the previous year 2008.
Omnimmune Seeks Financing
08/19/2009
Omnimmune Holdings, Inc. plans to raise funds. The firm said in Form 10-Q filed with Securities and Exchange Commission (SEC), Management is seeking to raise additional money through private debt and equity offerings to enable us to satisfy our cash requirements in the coming months and beyond and to fund ongoing research and development activities. We are not self-supporting through internally generated capital, and rely exclusively on our continued ability to raise additional funds through private or public debt or equity financings to meet our ongoing cash needs. We will require substantial additional funding in order to meet our obligations to our licensors, continue our research and product development programs, including preclinical testing and clinical trials of our product candidates, and meet ongoing operating expenses. We expect to continue to incur substantial losses through at least the next several years and may incur losses in subsequent periods. The amount and timing of our future losses are highly uncertain. Our ability to achieve and thereafter sustain profitability will be dependent upon, among other things, successfully developing, commercializing and obtaining regulatory approval or clearances for our technologies and products resulting from these technologies, which will require substantial additional funding, the availability of which is uncertain. A material shortage of capital will require us to take drastic steps such as reducing our levels of operations, disposing of selected assets, curtailing our development efforts or seeking an acquisition partner. If cash is insufficient, we may not be able to continue operations.
Omnimmune Holdings, Inc. financial resources
OMMH Competitors
| Company | Last | Change | |
| No competitor information is available for OMMH. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | OMMH | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
OMMH |
||
OMMH transactions
| Type Date |
Target |
|
Private Placement
January 20, 2010 |
-- |
More Recent Financial News About Omnimmune Holdings, Inc.
OMNIMMUNE HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi
2010-01-27 01:14:16
Quote: Item 1.01 Entry into a Material Definitive Agreement.
On January 20, 2010 (the "Closing Date"), Omnimmune Holdings, Inc. (hereinafter,
referred to as "we" or "us") entered into a Term Sheet for Debt Financing and
Agreed Upon Restructuring with Margie Chassman (the "Term Sheet"), and in
connection therewith, entered into: (i) subscription agreements (the
"Subscription Agreements") described below in Item 3.02 to sell up to $500,000
of unsecured c...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh
2009-11-30 08:03:57
Quote: Item 1.01Entry into a Material Definitive Agreement.
On November 21, 2008, Omnimmune Holdings, Inc. (the "Company") entered into a
demand promissory note, dated October 31, 2008, for the principal amount of
$287,768.40 payable to McDaniel & Henry, LLP, the Company's legal counsel, for
the payment of outstanding fees and expenses (the "Note"). The Note is payable
in cash on the written demand of the holder any time following the closing of a
"Qualified Financing"...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
2009-11-30 08:03:57
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Overview
Omnimmune Holdings, Inc. ("Omnimmune" or the "Company") is the holding company
of Omnimmune Corp., a development-stage biotechnology company integrating
complementary cancer therapeutic, diagnostic and prognostic technologies. Our
mission is to provide a comprehensive and personalized approach to the clinical
management of cancer through improved diagnostic, prognostic and ther...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
2009-11-30 08:03:56
Quote: OMNIMMUNE HOLDINGS, INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
OMNIMMUNE HOLDINGS, INC.
23-Jul-2009Change in Directors or Principal OfficersPrivacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, inco...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
2009-11-30 08:03:56
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Overview
Omnimmune Holdings, Inc. ("Omnimmune" or the "Company") is the holding company
of Omnimmune Corp., a development-stage biotechnology company integrating
complementary cancer therapeutic, diagnostic and prognostic technologies. Our
mission is to provide a comprehensive and personalized approach to the clinical
management of cancer through improved diagnostic, prognostic and ther...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 10-K, Annual Report
2009-11-30 08:03:56
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Overview
Omnimmune Holdings, Inc. is the holding company of Omnimmune Corp., a
development-stage biotechnology company integrating complementary cancer
therapeutic, diagnostic and prognostic technologies. Our mission is to provide a
comprehensive and personalized approach to the clinical management of cancer
through improved diagnostic, prognostic and therapeutic interventions. Omnimmune
has acquired licen...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princ
2009-11-30 08:03:56
Quote: Item 1.01Entry into a Material Definitive Agreement.
As previously reported by Omnimmune Holdings, Inc. (the "Company") in its
Current Report on Form 8-K filed on August 12, 2008, the Company completed an
initial closing of its unit offering (the "Unit Offering"), pursuant to which
707,200 Units were sold. At such initial closing, the Company entered into a
Registration Rights Agreement, dated as of August 8, 2008, with the investors in
the Unit Offering (the "Initial R...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 8-K, Other Events
2009-11-30 08:03:55
Quote: Item 8.01.Other Events.
On April 18, 2008, Omnimmune Corp. (the "Company"), a wholly owned subsidiary of
Registrant, entered into an exclusive license agreement with The Ohio State
University ("OSU"), covering, among other things, certain technology and patent
rights relating to a Her-2 vaccine (the "Vaccine") under development at OSU (the
"License Agreement"). By letter dated August 17, 2009, and received by the
Company on August 20, 2009 (the "Noti...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
2009-11-30 08:03:55
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
Overview
Omnimmune Holdings, Inc. ("Omnimmune" or the "Company") is the holding company
of Omnimmune Corp., a development-stage biotechnology company integrating
complementary cancer therapeutic, diagnostic and prognostic technologies. Our
mission is to provide a comprehensive and personalized approach to the clinical
management of cancer through improved diagnostic, prognostic and ther...Read article
OMNIMMUNE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
2009-11-27 22:29:28
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
Overview
Omnimmune Holdings, Inc. ("Omnimmune" or the "Company") is the holding company
of Omnimmune Corp., a development-stage biotechnology company integrating
complementary cancer therapeutic, diagnostic and prognostic technologies. Our
mission is to provide a comprehensive and personalized approach to the clinical
management of cancer through improved diagnostic, prognostic and ther...Read article
Would you like to leave a comment about Omnimmune Holdings, Inc. OMMH/OMMH.OB
Find out what social network information about Omnimmune Holdings, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Omnimmune Holdings, Inc.'s Stock there is more great penny stock and market information at Realpennies